CVAC - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Sarah Fakih

Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih and I’m the Vice President of Corporate Communications and Investor Relations at CureVac. Please let me introduce today’s speakers.

On the call with me from CureVac are Franz-Werner Haas, the Chief Executive Officer of CureVac; Klaus Edvardsen, our Chief Development Officer; and Pierre Kemula, Chief Financial Officer of CureVac. Technology be Chief Q&A for our Session. Fotin-Mleczek, Officer, available will the Mariola this webcast under is be note call Please that being our the and on archived events live presentations Relations section Investor website. on will and

we and to discussions reflect view your statements. Friday, today, call responses as this a of forward-looking on November Before begin, management’s The few questions XX, XXXX.

any beliefs, statements future. statements and statements. the provision. questions actual the our that from intention intentions, CureVac materially your forward-looking These of providing that the those could differ of forward-looking to making disclaims any expectations, responses be obligation Safe predictions will or These revise for risks We purpose statements cause constitute or and projected. to state Harbor results involve uncertainties to

filings call Franz. over I U.S. to information, and Securities refer Commission. to the For more will please turn with the now our Exchange

Franz-Werner Haas

from conference Thank us at you, to welcome Sarah. this warm Ladies gentlemen, from here, a call and CureVac.

to differentiated vaccines that made challenging are a where expected large-scale improved control vaccination while allow world me coverage, helped delivery vaccination CureVac to meet Recognizing develop initial to quarter licensed goals. manage brief And positioned broader well Let needs additional to the virus simplified protection, of still term. assessment more third situation, in vaccines continues. long and during the for decisions today. logistics this our XXXX with we The programs, fight these SARS-CoV-X of vaccines begin have to have against global and stand the

COVID-XX committed CVnCoV, potential decided product. be our factors combination and made withdraw and, a In on the based fast you GSK, third differentiated have second-generation selected from October year, lines the vaccine fight the me because this regulatory made decision late the overlap key of candidate we vaccine, a vaccines. first-generation review give to with we time developments partner, quarter. of second-generation COVID-XX, to included overview together first-generation toward needs decision with age-restricted our We strategic that with rather to the Let this than changing short remain long-term a a for against with an in

second-generation potential protein The proof of an a supported therapy, recently data in data as the technology therapeutic later. Journal candidate first neutralizing injected that commercially cell biopsies SITC. great In experimental our outperforms titers vaccine, of third first X update every several field showing The entire CvXCoV that potential provided data you by nonhuman preclinical to in CVXCoV substantiated as lead unmodified blood data updated technology. of antibody immune the tested shown molecular is BioNTech in recently developed an that immune published available data showing preclinical at fight from challenging Pfizer well era. CVXXXX with complemented entire a our oncology, by distant CVXXXX COVID-XX comparison we The responses this our to approach In potential our CVXXXX directly candidate primates therapy, mRNA which primates. are with published on induces in construct and mechanism And manner samples show second-generation Klaus approach has Nature mRNA These in models. of Phase CVXCoV, of option candidate of as in Hepatology. for mRNA preclinical it Deep noninjected body, recently tumors liver throughout area, activation can tumors. program presented that our in program, full Comprehensive the comparison jointly CvXCoV the parameter. nonhuman in we is mRNA serve data were therapeutic recently in as this support the direct first-generation the we highly analysis fibrosis, comparable was the technology for providing tumor induce able treatment unmodified our of renamed will yesterday, vaccine of that

Beyond to COVID-XX we other the our anticipated mRNA technology second-generation platform, needs the our are in and vaccines of infectious volume diseases. adjusting also manufacturing advancing technologies, capacity

financial our On closed third well we areas. this with as may provide all million. favorable of additional market XXXX accelerate our at to billion. development of of a €X.XX to to position side, Applying to conditions, therapeutic sell the the means potentially shares will facility technology company quarter up we as in the future conduct of Subject across US$XXX offerings cash market

step look with Before a a of would like we go of CureVac’s need. indications I to high a back diverse we and now to the provide diseases technology pipeline, where medical areas unmet these apply at program to updates, address and RNA take detail the

We it me many but repeat. The of just RNA times era has have said let technology please before, begun. only

in against was fight the mRNA a pipeline prophylactic the CureVac beyond. While and of as COVID-XX, three therapeutic vaccines, molecular range much broader main technology validated builds it oncology, indications therapy. areas: exceeds in to key vaccines on medical potential prophylactic Correspondingly, a its and

CVnCoV, infectious constructs. COVID-XX of vaccine collaboration with in developed well led program, vaccine by pipeline The GSK. disease both investigating unmodified as is as our unrestricted Following modified applies approach, the including candidate withdrawal first-generation the technology program our prophylactic mRNA an broad second-generation

vaccine. improved an – CVXCoV, of the comparison. the of shown broader first candidate, first-generation the already Pfizer BioNTech comminate first second-generation unmodified which As antibody program, in preclinically compared responses which representative direct infectious the has COVID-XX an titers the to In is vaccine, significantly immune matching a representative has the program our disease neutralizing influenza mRNA, is mentioned, non-COVID

assessed in and are First half where clear a tumor-directed learnings immuno-oncology, of range constructs a expected first translation we of of COVID-XX being principles is same strong induce applied the In for in preclinical XXXX. are approaches. There to immune systemic clinical study start are exploring a is oncology, the different to a models response. and currently

solid trial Our tumors. lead clinical assessed candidate, CVXXXX, in in X is a currently being Phase

shared therapy, intended we antibodies mRNA inactive third number or therapeutic of molecular partners for area, characterized a optimized treat novel also by proteins. or developing diseases together In to evaluating with are approaches neoantigens targeting are the tumor-associated therapeutics, proteins We the of cancer collaboration missing therapeutic development vaccines antigens. renowned to and

now me Klaus updates. walk to details over Let our call the hand through program you of to the

Klaus Edvardsen

and Thank everyone. you, Franz, hello,

X by to move prophylactic describing area. Slide me and vaccine our start Let

Let a developing disease other for second-generation me well briefly candidates we potentially GSK, remind infectious you improved jointly scope suite of the diseases. range with our in are of as vaccine of collaboration COVID-XX as broad broad of infectious which a

also expression advanced earlier to into of to extended RNA the for the are more multivalent stronger responses. vaccines an Our untranslated second-generation COVID regions against advanced protection flu. differentiated formats messenger COVID-XX, to these simultaneous in characteristics such COVID-XX be infectious for enable and vaccines for future the need different against diseases the ongoing variants and RNA Due will develop different featuring for messenger as translation based candidates, fight but a or and of protein vaccine to combination optimization on targeted setup improved key

our clinical As We construct within advanced slides. second-generation a explore of this will next I months the intend the platform trial. in development COVID-XX for an to and RNA extension preclinically few constructs messenger COVID-XX more to With of second-generation the program coming speak modified modified possible program, aim off kick within we first of about to on detail Franz before, to have which technology the also highlighted CVXCoV, candidates. the selection the representative includes allow large best data-driven

On the disease testing half is developed the enter infectious jointly side, XXXX. first preclinical construct currently in and flu our in the will clinic

the Neutralizing in how demonstrate the We to by our including messenger data, dose induced primates preclinical antibodies at from standard XX second-generation utilizing in of of just targeted vaccine comparable substantially vaccine. preclinical RNA also vaccination at non-chemically CVXCoV higher thereby, was variant. an to in demonstrating of Let the vaccination, antibody titers our excerpt potential me X, antibody the In licensed Slide relevance a to summary, comparison either animals. the Slide strong compared to or XX induced represent times a CVnCoV, improved when move CvXCoV, study, higher the now Pfizer demonstrate the recently utilizing and titers first of Comirnaty. briefly micrograms on peak highly approach of titers pre-print CVnCoV, messenger X, neutralizing range onset a direct COVID-XX CVnCoV here vaccination. antibody for The five, construct full immunogenicity overall large Harvard Nature Comirnaty. after CVXCoV were The a shown second of micrograms with to server relevant data following compared one led published immunity utilized can go by the the of as higher Faster fully data Delta I observed which two week for CVXCoV the to about features X animals CvXCoV a XX were antibody At licensed non-human the which now direct into titers significantly variants, primates RNA. which data after exhibit set comparison extended CVXCoV optimization of week the modified In Medical response messenger of titers with of the weeks understanding nonhuman by CVXCoV of whole. times technology Consistently BioNTech preclinical baseline. still in meaningful bioRxiv’s comparison improve in collaboration potential initially yesterday. study. generated study of data the preclinical were uploaded CVXCoV with online School, in levels measured of unmodified to

evaluation me to progress currently like lead under you clinical oncology Let Slide pipeline. trial. of move candidate on I our would to on describe Phase our the update X part X the CVXXXX, a in to

head into When are reject injected that called RNA tumor CVXXXX cells hypothesized release as immune including remind seven of viruses, that tumors RNA non-coding initiated The administration cells part and viral of detect you The agent clinical single cystic is is been Let the or skin a carcinoma. tumor, Phase advanced at dose-escalation in directly can RIG-X. combination to part and response melanoma, party T two-part of is Patients CVXXXX activation CVXXXX this the eight induced June which anti-PD-X in neck completed, activate this locally briefly update from trial patients presented efficacy also of is the February expansion CVXXXX study, in from tumor. the infection study distant receptors a X in tumor, of non-injected carcinoma the well cell as the data with to throughout at amplified already the of receptors antigens able injected received study. adenoid in tumor-specific the melanoma. tube clear and you metastases. squamous dose-escalation in injected a has or at see cancers, can the as year the me to specifically new on on year, therapy. to with of is with advanced the normally latest system The the year September. the patients If XX, activate trial XX a ESMO evaluate evaluating part Slide we and the CVXXXX that were move immune mimics but a toll-like CVXXXX this and It conference cutoff tumor additional the represents earlier based the site, that date an optimized

pretreated left, a for a evidence including one patients with patient did patient can indicated on single-agent lesion non-injected for patients. one patient response well as experienced carcinoma. the respond of On slowly disease, anti-PD-X activity group be a a The cutaneous and shrinkage the heavily complete squamous Overall, combination partial stabilization therapy. and a on in of one who not or some in progressed with patient therapy includes right response in who partial in anti-PD-X melanoma with response as were cell same more of observed

response patient disease observed partial could a patients experienced as So patients with stable melanoma head neck far, well cancer. further be one and and two melanoma with two as

order T presented muni non-injected able Moving into At Phase a non-injected part. four patients. based in The blood the injected the to and infiltration the of tumor Blood will of an SITC broad injection data CVXXXX the including against Data, tumor that well profiling hours understanding study, of be interferon cells The T and the is of as second we immune activation system cell of tumors. by local a samples X recent and CVXXXX. effects tumor injected half in last gamma. on increased by CDX the samples to Phase the alpha and corresponding leading from immune complement to the response, therapeutic single after is enrollment October. to within cell in confirm XX week, CDX injection, biopsies innate on from as our Tumor produce CVXXXX support In is the data was data Slide of confirms to in a interferon the content. mainly completed decrease systemic for and over biopsy XXXX tumors both patients characterized X both from of conference data all further expected of biopsies expansion hypothesis patients patient effect of further dose-escalation strongly XX. part reported the details additional XX and patients of

transition turn third area XX me and or renamed into molecular as recently our pipeline, to Slide we the Let in protein therapy. have therapeutic therapy, it

out HNFX millions carried area, HNFX fibrosis, or As liver Franz published debts To can for fibrotic level center disease able cells, the development of by with on the Progression of RNA data This that the was recently is the as protein to provide healthy serve fibrosis potential this therapies liver missing first and for liver associated this efforts metabolism. preclinical let we of graph. this, to administration option demonstrates circumvent right development molecular restore alpha messenger of levels indeed that research reduced HNFX of developed and of study can damage. messenger inactive by promising study contributes of a left mice. encoding in disease illustrated reduced with to School. alpha for a induce middle the has data protein proof indicator Correspondingly me on to in of liver RNA alpha a restore Franz. significantly in inside technology we optimized in and and our at target the the these messenger decrease as liver the production RNA HNFX decrease, that experimental our liver The alpha was an versus to mouse reduction already HNFX a back With the illustrate shown injury. to optimized ALT, messenger in animal is fibrotic therapy is potential RNA call collaboration able highlighted, characterized The Overall, Medical was messenger gradual In hand proteins annually. therapeutics molecular this essential fibrosis. in that the missing provides Hannover alpha, proteins. treatment replace RNA shown

Franz-Werner Haas

our of I’m you, Slide now current plans Klaus. manufacturing Thank you capacities. overview on the XX give to for an

the our flexibly first we capacity deliver as that second continuously are as in network and specific new processes vaccines construct We the switch volumes. The program. includes our GMP the for ensure of setup the adjusting the modified for anticipated as projections construct, our of well we second-generation facilities to potential to This of second-generation can rapidly of the with three implementation progressing. facility at from production line in-house and adoption manufacturing variant of mRNA flexible production European processes which of constructs the to explore part partners is development generation

clinical trial also plant upcoming on produced and buildup The have deliver four X planned, our manufacturing progressing important of preparedness Phase two. in pandemic an CVXCoV, our in representing factor GMP plans, the GMP one to public and For future our is setup efficiently health initiatives. commercial-scale already for needs we as material in-house

Let hand data. review Pierre to me for now over financial of a our

Pierre Kemula

good Thank you, morning the call. and afternoon Franz, and on to good everyone

financial our this worth an future second-generation executing market $XXX up the to areas. to further transition accelerate vaccines We which, the progressing the to up tool in period financing, from we our technology the program have to set momentum strategy. over able to on with conditions, to use us fund first option the to while vaccine from our we across a year, million may September in subject the are first expect shares offer as provide If successfully to future, in Early well provide transition use the therapeutic years. mRNA means we proceeds as are second-generation of at-the-market several to at-the-market of the the

to discussion with signed have the we impact that anticipated on into purchase you review, semifinished from go expenses to briefly advanced the financial committed EU or the on XX, APA, and upfront of And must a the return unspent CVnCoV with me we focus P&L the the a the of restoring the reported we using submitting the only the European According Commission to agreement let on amount cash are prepayment. stage, in of the of of we payment. payment. Before to structured future At this update portion providing expenses XXXX. Slide regulatory European process assets, that assessed financial we we the that to goods no CureVac the our a be share efforts the Commission Commission to XXXX. safe will expect €XXX of finished efficacious it. and million risk certain that The of will and in of has required do not and APA develop return be value quarter by The vaccine the European fourth any in accelerated November will use have upfront

materials We with me exercise under With it are for the evaluate components Commission to will its recover to with the options that, the or currently has APA. resume primary some coordinating raw European the whether paid let review. financial allowed upfront

Looking €X.XX XXXX cash at closed position, of third with our favorable current quarter cash position the of billion. we a

the of and our the for Cash of of payment raising Federal €XX cash extension net from a with million mainly proceeds mainly months following used €XXX by Education million €XX.X first German of the follow-on was grant the quarter, and of the a million was Ministry driven CVnCoV. Research. first GSK development in tranche Over collaboration QX upfront development from the our from the in position offering our in the nine XXXX,

by €XX.X GSK €XX.X was million the our XXXX. €XX for first from to of quarter in Moving of XXXX, to €XX.X same for months the on and which first increased to statement. nine year the million our Revenues driven compared the collaboration, for loss the profit of revenues mainly million months to million revenues XXXX. million in increase €XX.X The third and periods provided nine

In for remaining cell collaboration addition, our cancer fully is now on recognized. termination to this of payment the upfront agreement of related year. November The became effective in Ingelheim contract non-small lung legacy clinical Boehringer candidates liability XX the

nine was a million as XXXX. offset XXXX, compared to €XX.X quarter quarter, These being revenue, increase the the onetime XXXX. the led €XXX.X third in were partly increases period XXXX. of €XX this the a by in million Operating million in months a to for representing million loss €X.X compared to For first second of effect €XXX.X same million recognized

activities sales, loss first the was from and including the based income operating and and the from messages. loss decreased million million the Overall, by operating of an CMO Research. key CVnCoV several Pretax million to negative €XXX.X Financial I €XXX.X foreign in and our on strong offset held XXXX. the like general of The by Education to increased and third With increase were cost manufacturing within CVnCoV the development expenses line to development to funds third of almost network. today’s costs in partially and quarter for as liquid for These with increase was and Net nine this, over quarter as was nine €X.X European losses months, exchange For activities, by would months back €XXX.X our higher other latter interest months expenses on takeaway first to first of of nine the increased termination throughout fully Franz results overall of Ministry in million CVnCoV Federal million €X.X by mainly €XXX.X hand €X.X driven increase were million high support strong a German the expenses the in well It offset manufacturing gains. resulting in XXXX. increased million R&D manufacturing CVXCoV. was to €X.X million. based cash in on contracts XXXX. by administrative by grants

Franz-Werner Haas

Pierre. you, Thank

fight fully today’s committed CureVac COVID-XX. messages summarize Let the to me the quickly against global key from remains presentation.

of delivering Being technology technology broad between accelerate has an a recently to are of of the our second-generation to needs. data COVID-XX, now Learnings in both of including advanced Highly of priorities the infectious our of and of We like this post-pandemic be sides. parallel which pandemic and will development first-generation unrestricted modified our therapy. the conclude with will dedicated shown pipeline the to resources across global platform companies, entire pipeline addressing on expected leveraged ensure mRNA and and to entire assessed will to future questions. constructs. together from deliver mRNA on, approach to vaccines, the our dedicated best we CvXCoV take goal we healthcare focus the selection two the experts with an advanced and potential mRNA disease infrastructure large relevant data-driven we preclinical and platform Further candidate. vaccines to in by GSK, momentum your to approach, molecular of presentation second-generation accelerate number advance fully priorities oncology unmodified vaccines common open and webcast program, competitiveness our for be and candidate supported aligned goal, With and are to therapeutics a this, the would candidate

Operator

with you. [Operator the question Our line Bank. with Thank of Mastorakis comes Deutsche question. your Manos first proceed Please from Instructions]

Manos Mastorakis

is for of what funding main taking what is I are for run rate wanted the business to the question. implications Hello. for my the [indiscernible] Yes. ask the Thank outlook The XXXX? moving forward? expected And question you in

Pierre Kemula

Yes.

the speaking, take Pierre So to question. happy

much because So in I the try me this let think budget it very are way we to still phase. answer

And it. comfortable. some this if feel of an position I is decline But the year, cash don’t at our time we’ve But the over and, bit to will to next spend all we – provide we should what put mean, the spend a that interest, in indeed, final investor ATM I course, as be So you color. was XXXX is use for cash point, that, figures think being, there’s yet to you have had place only happy we right? we able cash more so said, to be

Operator

you. Thank

of question Please Guggenheim Securities. question. from Wang the Evan with your proceed with line next comes Our

Evan Wang

some terms same you terms to additional schedule CVXCoV response? of dosed of share clarify Hi, guys. in to clarify renew see of whole monkeys you XXXX When between And plan want antibodies I kind comparison the compare? where do of there time the lines nature will neutralizing of publication. the a pay the we the can a Comirnaty? And guys kind of aspects Do and data kind in kind in peak or follow-up. little Comirnaty of XXXX? I And bit how then have the of

Mariola Fotin-Mleczek

Okay. Mariola by speaking. we are In this be with one a not There is which showing the how compared study, – we and vaccination Lab, from here candidate. collaboration vaccination future schedule, data coming this using separate study on typical have yes. Ten our on in set Comirnaty used just here. is for will antibody But a schedule us titers for

have will data coming soon. we So more

Evan Wang

remaining I Great. of guess, And before are there? I what – what And confidence as starting mean, trial? study the follow-up, comparable level the a the does give given the results clinical this hurdles you

Klaus Edvardsen

Klaus Hello. Hey. hear is Can you This here. me?

Franz-Werner Haas

Yes, please proceed.

Klaus Edvardsen

different Yes. I just out and would modalities therefore, the essence, It’s there be simply we of going to test a second into the is, alluded like we it’s are have a with to hurdle. we under out. presentation combination that approaches are to that not test generation mean, the no there to effort hurdles go as ready – to in

Franz-Werner Haas

to months And we are collaboration GSK. within in with start the come in next preparation the trials to clinical

Mariola Fotin-Mleczek

a CvXCoV be good for has chance data also that also a solution. construct supportive, to the And good yes, our

decide same, which construct we memory – modified, data, trial the look always our mechanism we As immune for unmodified face development. be the exactly future four solution this then of the the on action responses constructs knowing that yes, and exactly could mentioned, is not the the of beauty the response, will different and on is for

Evan Wang

Thank you.

Operator

Thank you.

proceed the of Evercore question Jonathan Our ISI. question. comes Please next Miller with your with from line

Jonathan Miller

am there. try locked I the that on, you your mentioned mRNA? going have multiple And using modified around said guys. see things. to you’re you. what guess, level to previous you to clarity a gets modified guess operate you’re what’s have unmodified, your And you second-gen I the modifications guess, also very what’s Hi, freedom space IP on started are? excited I usually in just question, in what I following Thank trial your or is comfort down

Mariola Fotin-Mleczek

different So, that comment be we tested cetera, use And variants delta, be consider as will use also I this can here this just different on modification well. will not it et one. also modifications,

Franz-Werner Haas

And then field, there well licenses as certainly, with IP to important of needed, if as to are certainly, on certainly part. the situation the operate we’ll an be certain course, then is deal print we,

Jonathan Miller

if guess Okay. to not sense. pursued follow-up I you what’s I your important IP the that be point? guess this confidence that makes at have get have there is, overhangs, yet on licenses modifications you’ll licenses that able

Franz-Werner Haas

are We confident as, are we parties. quite of course, relevant talking with

Jonathan Miller

Okay. Thank you.

Operator

Thank you.

Berenberg. Please your question. Our next question Shu proceed comes from the Zhiqiang with with line of

Zhiqiang Shu

you. Thank Great.

you this also the MRE – guess working with a would So follow-up. they the around I a unmodified Thank guys? that you. questions unmodified. on in what effort? second-gen around And on have to collaboration modified, I are GSK, modified, then of contributing with And they be couple just together

Mariola Fotin-Mleczek

our started know, on already generation the you XXXX. in efforts as second we So

So yes? lot one, And – we designed not we same when a in GSK the closed of the we constructs just collaborations. then step-in and same different this generated this construct, with based data, technical on data and models

exclude with design how is this modified, question see knowing the approach and and to any from from the outside or this therefore, the approach. whether yes? don’t options. competitors, what want is also sure, invest compared we And obvious coming results initial the to coming for the this further effort CureVac, we So we And

included and absolutely said, data-driven mechanism our to want I decision be to as our action we this are the learn, to and That’s and what make GSK, our data. the of trials, partner, As from in the also on identical. as really intention what this well based not goals that’s we and is

Franz-Werner Haas

was monovalent it? Perhaps to and now. add the vaccines, a they compete GSK, how just and into for only we collaboration the have to the two turning part pandemic, It’s or a had vaccine with as intensening to which the what well. ago, a it had entire with this is the we is are or quite adding endemic market. webcast not as are our question, also broadening to To from GSK’s one with this of in which It current into to is with just three weeks situation, right current well, deal

about a that backbone, of also same on to combine – mRNA-based about the put the or thinking with into the run, have long the different cocktail same monovalent, – same longer got thinking and a short also you about multivalent it’s variants with antibody not and backbone So it Then only other other then vaccines protection titers also vaccines. the on life.

lot where a with certainly technology. immune top and understanding the GSK, to of the how to organization company of from virology develops, are tackled, adding that changing commercial they’re by all this system an So also into of the on the biotech also a be certainly broadening a company questions lot and that,

the bit. on with are but level, technology have a therapies. is before molecular not the is level, other level, And outside done with elements lot this working – things the On modification, pipeline what quite with the well on Broadening immunomodulators, all be known, immuno-oncology the tells of but for contributing this field GSK there also chemical then you one the antigen what also the level. and the Mariola we formulation also broadening to as only play saying a with which on are RNA technology of to was one

we need alone they be really bring that is a the not which to So because time to we could there aspect also accelerate. is table, what what

Zhiqiang Shu

you your run to related have doses? trials, people them give a early, it’s guess, you. looking development for strategy like know are you booster that, Or the people the but you’re at second for ask this Thank vaccinate also clinical I’d I And market. Got this the market looking for generation with – market. when are then my to to primarily European know here. question generation, been And and is second first booster? you looking around in vaccinated probably your probably who is two it. clinical in I asset, I

exchanged looking you. point? the at everything are you Europe market that and this Thank U.S. at with both Now the

Klaus Edvardsen

important are the development it And can into whether market will with plan boosting both and doing for more I a important, has second-generation level and part structured clinical you the hierological looking by program scientifically, interesting the the level different or COVID booster with U.S. been of different also of to is of reactogenicity look start Yes, setting. I get question at first. the efficacy, understand principle. last to the think potentially even a we

being I on it But element variants have other setting European world be an should prepared one a where delta ongoing There’s infected. the today, conduct the on of you with for a this being structured. and significant obviously certainly of speculation you. effort. correlates an geography, conduct guess, you of a as the of are how trial how there’s the it’s do how not element of proportion and program. your Thank implied that’s variance with in And you that do priming there program of global the a concept. speculations is question effort, vaccinated discussions the obviously also a certainly or So in trial on only protection about

Zhiqiang Shu

very you Thank much. Great.

Franz-Werner Haas

is and still vaccinated. Perhaps interest, the the buy future huge to this question for for the we see I you who as into governments pandemic to are markets a of one to prepared because people not a there increasing coming because incidences are tender lot add still what be mean, now well. market are a there a asked associated as into, with to and there markets

others probably changing also today, And again, in. vaccines see the environment, what in to be for also pandemic coming in situation. new most priming with and the perhaps certainly vaccines to are and boosters we, the deal vaccinated variants So

So there’s a of lot and of on need question to kind stability as well. work this

Zhiqiang Shu

Great. Thanks very much.

Operator

next of proceed you. Thank instructions] from of question. line America. comes Meacham Bank question with with your Geoff Please [Operator the Our

Aspen Mori

Aspen Hey, the on Thanks guys. for It’s for question. Geoff.

target strategy Just agreements guess, us at? – line one. already regarding looking bodies the for some what that discussions And and of CVXCoV? kind for just Thank of some CVXCoV regions had you. the want with I maybe help contract discuss for you’re more, government you’ve help on characterize in your be last follow can might Maybe that the time to up you

Franz-Werner Haas

utmost different we XXXX enter decentralized is in in where cannot is – available situation for Yes. XXXX Thanks really into to of under XXXX. go for beginning and have we, perhaps the learned all because which in discussions, I of is question. a locations, the the in capacity the of lessons is manufacturing clear importance in to take need what can twofold. the because wants no think been unfortunately, The government see there one details But Well, this one, confidentiality. a

vaccines with you be that With are to flexible would the vaccines but the increasing for we certainly, filled, that units a current going is is there is that which see look have the well vaccines. even also vaccines probably because, current otherwise, variant the most got covered if by the care different. the understanding good there not And incidence world and more an vaccines, intensive

products translates a this be Europe, So from beginning, to then and there in is been also need one, in it is has this this into like how still the ongoing. pre-purchased

but to So this see This international the to current for see global regulatory entire a community. pandemic, only you and the economy come in been international that a also has only up something seeing. and GX what social effect, what approval going how in we is processes but level. not the come also and also can come accelerate have level tendency not – can horrendous the on we GXX the the health what and world like is on What clear is is say we else

as on willingness work like and a And current built be platforms. the beyond have years. on to to ours XX even seen, clear a is, there interest technologies have we situation, So

a the in it also at you’re prophylactic technology, in are finish this pathogen speak. state you clear as and would to the much least closer coming well are much so But they from that faster, understanding which Now see exploitable. question. much is fill to have produced be then mine a a situation example, flu-like a tendency There contribute, in where, if make for vaccines, better to to target soon in which real season on rather can now and

So, I unfortunately, cannot I, and talk discussion huge about. said, therefore, as a interest, negotiations, concrete a is there about

Aspen Mori

Thank you.

Operator

Thank you.

Please from proceed Our with Manos next your of follow-up with Bank. question line question. the is a Mastorakis Deutsche

Manos Mastorakis

you’ve question. there approval? Basically, taking X Is I wanted for around Phase about you study to Yes. But lines next be a beyond you for [indiscernible], Thank that need head-to-head will something think year. you full be already? for a ask time for our do that, U.S. thought that mentioned it would

Klaus Edvardsen

that this obviously the too say. that conduct think I’m of can as notion in scheme. think for accepting different a necessity this ongoing conversation stage, early your a I at is to And correlates you to they aware an I fully FDA is there protection. not, are whether of trial

obvious and country to non-vaccinated, wait obviously, the that in think world. it’s the the Phase you to year talking if conduct and one two a U.S. from conduct is now, I two the also in with to around the that then U.S. are vaccinated going a trial see design about one difficult until countries the like be groups, X could traditional rates you in in groups increasingly and be infection

this and revisited assessing stage, the have not you especially I slow whole then trials from in down advances for at up different absolutely willing a aspect in withstand I these will if obviously, confident am it be will feasibility efficacy to opened are strong right they to that you are because they it naturally because will current before traditional So is stand. correct infected, vaccines FDA a from of it people vaccinated FDA they come been an or so But are that new find if that speak the in either way. net into taken it now, have more have cannot difficulties to perspective, doing way

Manos Mastorakis

Okay.

Operator

floor question-and-answer concludes turn for Ladies gentlemen, you. I’ll final and Ms. the Fakih back any our Thank to comments. session. that

Sarah Fakih

With Stay to this, this participation. further Thank have to your conclude don’t should you like you. call. and Thank Thank conference hesitate much please you contact we you, and any questions. goodbye. for very would safe, us

CureVac (CVAC) 19 Nov 212021 Q3 Earnings call transcript